EUTOS Registry Represents Benchmark for Evaluation of New CML Treatments

EUTOS Registry Represents Benchmark for Evaluation of New CML Treatments
EUTOS Registry Represents Benchmark for Evaluation of New CML Treatments

The population-based EUTOS registry demonstrated high overall and progression-free survival rates among patients with chronic myeloid leukemia (CML), according to a study published in Leukemia.1

The EUTOS registry includes data of all adult patients newly diagnosed with Philadelphia chromosome-positive and/or BCR-ABL1 CML in 20 countries and regions of Europe. Median age was 55 years and median observation was 29 months.

Of the 2904 patients included in the analysis, 80% were treated with imatinib in the first-line setting, while 17% received a second generation kinase inhibitor, such as dasatinib and nilotinib.

After 12 months, the complete cytogenetic response rate and major molecular response rate was 57% and 41%, respectively. Those with high EUTOS risk scores were more likely achieve a complete cytogenetic response and a major molecular response later than patients with low EUTOS risk scores.

At 12, 24, and 30 months, the overall survival rates were 97%, 94%, and 92%, respectively. Progression-free survival rates at the same 3 points time points were 95%, 92%, and 90%, respectively.

The investigators also validated the ELTS score for predicting overall survival, as overall survival differed significantly between the 3 risk categories.

The responses and outcomes observed in this population-based study were similar to those reported in clinical trials.


1. Hoffmann VS, Baccarani M, Hasford J, et al. Treatment and outcome of 2 904 CML patients from the EUTOS population based registry. Leukemia. 2016 Aug 29. doi: 10.1038/leu.2016.246.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs